Hemoglobin News and Research

RSS

Community health team improves diabetes control in Polynesian community

A team of community health workers has been able to improve control of Type 2 diabetes in a group of individuals from American Samoa – a medically underserved territory with a high prevalence of obesity, diabetes, and other cardiovascular risk factors, report researchers.

25 Feb 2013

Quest Diagnostics signs definitive agreement to sell HemoCue business for $300 million

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it has signed a definitive agreement to sell its HemoCue diagnostic products business to Radiometer Medical ApS for a purchase price of approximately $300 million plus customary adjustments for cash balances.

From Quest Diagnostics 25 Feb 2013

Dabigatran decreases risk of recurrent venous thromboembolism

New findings from two double-blind, randomized trials, RE-MEDY and RE-SONATE, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE).

21 Feb 2013

Tranylcypromine may also hold promise in treating sickle cell disease

An antidepressant drug used since the 1960s may also hold promise for treating sickle cell disease, according to a surprising new finding made in mice and human red blood cells by a team from the University of Michigan Medical School.

19 Feb 2013

New study reveals how control of brain blood flow develops with age

A new study by Columbia Engineering researchers finds that the infant brain does not control its blood flow in the same way as the adult brain. The paper, which the scientists say could change the way researchers study brain development in infants and children, is published in the February 18 Early Online edition of Proceedings of the National Academy of Sciences (PNAS).

19 Feb 2013

Findings add weight to WHO malaria pregnancy guidance

Pregnant women who receive three or more doses of malaria preventive therapy have higher birthweight babies than those who only receive two, conclude the authors of a meta-analysis.

18 Feb 2013

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Genzyme, a Sanofi company, today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, its investigational oral therapy for Gaucher disease type 1.

15 Feb 2013

Masimo's total fourth quarter revenue increases 18% to $132.2 million

Masimo today announced its financial results for the fourth quarter and year ended December 29, 2012.

15 Feb 2013

Combined genomic and proteomic plasma analysis can identify molecular disease mechanisms

For the first time, scientists have combined genomic and proteomic analysis of blood plasma to enhance identification of genetically regulated protein traits. This could be applied to any large association study of civilization diseases where blood plasma has been collected, vastly improving a clinician's ability to identify disease susceptibility in individuals and populations.

11 Feb 2013

Diabetic peripheral neuropathy risk highlighted in children

US researchers call for clinical guidelines for detection of diabetic peripheral neuropathy in children after finding that a significant proportion of young patients are affected.

7 Feb 2013

Glycemic control low priority in diabetes CVD prevention

Maintaining glycemic control does not reduce the likelihood for cardiovascular disease leading to hospitalization in people with Type 2 diabetes, report US researchers.

4 Feb 2013

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

The U.S. Food and Drug Administration recently announced the authorization of FerriScan R2-MRI to be marketed as an imaging companion diagnostic device for the safe and effective use of Exjade in patients with non-transfusion-dependent thalassemia.

31 Jan 2013

Nonin donates six Onyx 9500 finger pulse oximeters to Evangelistic International Ministries

Nonin Medical, Inc., the inventor of finger pulse oximeters and a leader in noninvasive medical monitoring, announced today that the company has donated six Onyx 9500 finger pulse oximeters to the Evangelistic International Ministries (EIM) for use at the Hospital Centro Socorro De Lo Alto in the remote village of Sula, Honduras.

31 Jan 2013

Libya becomes the first country to use Masimo Pronto-7 hemoglobin spot-check device

Masimo announced today that Libya has become the first country to begin using the Masimo Pronto-7— a handheld noninvasive hemoglobin spot-check device — to screen potential blood donors for low hemoglobin level in all of its major blood-donation centers.

31 Jan 2013

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes (MDS).

30 Jan 2013

TAPS supports preoperative transfusion

Preoperative transfusion may protect sickle cell patients from surgical complications, suggest findings published in The Lancet.

29 Jan 2013

Paper says hospitals that do treat patients with anemia have better outcomes

Up to one-third of patients undergoing surgery in Ontario have a treatable form of anemia but are not optimally treated for it.

28 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Leading-edge Masimo medical devices to be displayed at Arab Health

Masimo returns to Arab Health Jan. 28-31, the world's longest running healthcare exhibition and congress held each year in Dubai, UAE, to showcase advanced, noninvasive patient monitoring technologies – including breakthrough SET Measure-Through Motion pulse oximetry and rainbow Pulse CO-Oximetry – that are becoming the standard-of-care across the Middle East.

28 Jan 2013

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

The U.S. Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets.

28 Jan 2013